Inactive Instrument

Vical Incorporated Share Price Nasdaq

Equities

Duration

Period

Style

Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-15	CI
Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index	12-21	CI
Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index	12-18	CI
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates	20/09/23	MT
US Futures Rise Modestly Pre-Bell as Investors Await Fed Rate Decision	20/09/23	MT
Top Premarket Gainers	20/09/23	MT
Fresh Tracks Therapeutics' Board Approves Liquidation Plan; Shares Rise After Hours	19/09/23	MT
Fresh Tracks Therapeutics, Inc. Announces Chief Executive Officer Changes	19/09/23	CI
Fresh Tracks Therapeutics, Inc. Announces Executive Changes	19/09/23	CI
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Fresh Tracks Therapeutics, Inc. Announces Resignation of Robert B. Brown from the Board of Directors, Effective Immediately	25/07/23	CI
Wall Street Set to Open Higher, Investors Look to End Week on Positive Note	21/07/23	MT
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Earnings Flash (BBI) FRESH TRACKS THERAPEUTICS Posts Q1 Revenue $9,000	10/05/23	MT

Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates	20/09/23	MT
US Futures Rise Modestly Pre-Bell as Investors Await Fed Rate Decision	20/09/23	MT
Oppenheimer Adjusts Fresh Tracks Therapeutics Price Target to $4 From $9, Maintains Outperform Rating	14/11/22	MT
Oppenheimer Adjusts Price Target on Fresh Tracks Therapeutics to $9 From $1, Maintains Outperform Rating	27/09/22	MT
HC Wainwright Adjusts Brickell Biotech's Price Target to $4.50 From $2, Keeps Buy Rating	16/08/22	MT

Fresh Tracks Therapeutics : Termination of Material Agreement - Form 8-K	03-07	PU
Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th	02-14	AQ
Fresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15th	12-27	AQ
Fresh Tracks Therapeutics Announces Listing on OTC Pink Market	12-19	AQ
Fresh Tracks Therapeutics Announces its Common Stock will be Suspended from Trading on Nasdaq at Open of Business on December 19th	12-18	AQ

MÄRKTE USA/Uneinheitlich - Zinspfad ungewiss	08/03/23
MÄRKTE USA/Uneinheitlich - Zinssorgen bleiben präsent	08/03/23
MÄRKTE USA/Wall Street mit leichter Erholung	08/03/23
MÄRKTE USA/Wall Street stabilisiert nach Vortagesverlusten	08/03/23
MARKT USA/Wall Street stabilisiert nach Vortagesverlusten	08/03/23

Managers	Title	Age	Since
Albert Marchio CEO	Chief Executive Officer	72	30/11/20
Nancy Seretta CTO	Chief Tech/Sci/R&D Officer	-	31/12/15
Aaron Fox-Collis AUD	Comptroller/Controller/Auditor	-	30/06/20

Members of the board	Title	Age	Since
Albert Marchio CEO	Chief Executive Officer	72	30/11/20

Fresh Tracks Therapeutics, Inc. is not engaged in any business activities. The Company is in the process of dissolution.

Sector

Calendar

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B